Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
> Listen on Spotify > Listen on Apple Products > Listen on Amazon Music > Listen on iHeart > Watch…
Category: Novartis
Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
Novartis’ Zolgensma has faced its share of controversy. Now, the spinal muscular atrophy gene therapy is making the rounds on…
Novartis puts $772M BioArctic deal on ice, skates away from brain-delivery alliance
Novartis is icing out BioArctic, abandoning a neurodegeneration pact that could have been worth more than $772 biobucks for the…
Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues
Novartis has pulled the plug on a Phase 2 study testing the complement blocker Fabhalta for patients with lupus that…